TY - JOUR T1 - Short-term antibody response and tolerability of one dose of BNT162b2 vaccine in patients receiving hemodialysis JF - medRxiv DO - 10.1101/2021.03.30.21254652 SP - 2021.03.30.21254652 AU - Rémi Goupil AU - Mehdi Benlarbi AU - William Beaubien-Souligny AU - Annie-Claire Nadeau-Fredette AU - Chatterjee Debashree AU - Guillaume Goyette AU - Caroline Lamarche AU - Alexander Tom AU - Andrés Finzi AU - Rita S. Suri AU - on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/01/2021.03.30.21254652.abstract N2 - Background Patients with end-stage kidney disease receiving in-center hemodialysis are at high risk of exposed to, and dying from, SARS-CoV-2. As impairments in both humoral and cellular immunity are common in this population, their response to vaccination against SARS-CoV-2 is uncertain.Methods We have followed in-center hemodialysis patients in the Réseau Rénal Québécois since March 2020 with serial PCRs for COVID-19 and clinical outcomes. Plasma samples were taken from 58 patients from one center before, and 4 weeks after, vaccination with one dose of the BNT162b2 mRNA vaccine. Anti-RBD (region binding domain of the SARS-CoV-2 Spike protein) IgG levels were measured using ELISA and compared to levels in 32 health care worker (HCW) controls, as well as levels in convalescent plasma taken from 12 hemodialysis patients 4-12 weeks after COVID-19 infection. Patients were stratified based on evidence of previous infection with COVID-19 (positive PCR or antiRBD detectable at baseline).Results Compared with health-care workers, hemodialysis patients without prior COVID-19 exhibited significantly lower anti-RBD IgG levels 4 weeks after vaccination (p=0.0007). Anti-RBD IgG was non-detectable in 1/16 (6%) of HCWs, and 25/46 (54%) of dialysis patients (p=0.0008). In dialysis patients previously infected with COVID-19, mean anti-RBD levels were significantly lower than their HCW controls (p=0.0031), but not signficantly different than those in convalescent plasma of recently infected dialysis patients (p=NS). No patients reported any symptoms 7 days after vaccination on a standardized questionnaire.Conclusion The BNT162b2 vaccine was well-tolerated in hemodialysis patients, but failed to elicit a humoral immune response in >50% patients by 4 weeks. Whether these patients develop antibodies or T-cell responses after prolonged observation requires further study. Until then, we recommend that rigorous infection prevention and control measures in the dialysis unit and outside of it be continued to prevent SARS-CoV-2 infection in this susceptible population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Canadian Institutes of Health Research (CIHR) Rapid Research COVID-19 funding opportunity. This work was also supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'Innovation to AF, by the Fondation du CHUM and by a CIHR Foundation Grant #352417 to AF. RS, RG, ACNF, and WBS are supported by the Fonds de Recherche du Québec Santé (FRQS) Clinician-Researcher Awards. AF is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235950-232424.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comité d'éthique de la recherche clinique du CR-CHUM and l'Hôpital Sacre-CoeurAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified aggregate data is available upon request to the lead author, RS (rita.sur{at}mcgill.ca), provided the necessary institutional approvals are received. Further information on the assays used and requests for reagents should be directed to and will be fulfilled by AF (andres.finzi{at}umontreal.ca). ER -